ERBB2 and neoplasm: Patient-derived tumor P54 is the only sample to have next generation sequencing (NGS) performed in clinic, and was found to harbor 5 mutations per megabase of DNA, which is close to the median for CRC.29 Sequencing revealed a KRAS G12V mutation but wild-type BRAF and NRAS, APC I1307K mutation, TP53 R175H mutation, and amplification of ERBB2, CCND2, FGF23, FGF6, and KDM5A.